Trial record 1 of 5 for:    sgn-33
Previous Study | Return to List | Next Study

A Study of Lintuzumab (SGN-33) in Combination With Low Dose Cytarabine in Patients 60+ Years With AML

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Seattle Genetics, Inc.
ClinicalTrials.gov Identifier:
NCT00528333
First received: September 10, 2007
Last updated: June 18, 2013
Last verified: October 2011
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been completed.
  Study Completion Date: August 2010
  Primary Completion Date: August 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 7, 2011